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ABSTRACT:
Stroke is an important cause of secondary epilepsy, especially in the elderly. Not only does this impact morbidity and
mortality in an adverse way, it also prolongs the hospitalization. Various risk factors have been described in literature
that increase the risk of seizures in a patient with stroke. Post stroke seizures fall on a spectrum of acute symptomatic
and unprovoked seizures with varying pathophysiology and risk of subsequent development of epilepsy. Hence, the
treatment approaches are also different. However, randomized controlled trials are lacking to guide monitoring and
management strategies in post stroke seizures and the approaches remain individualized to an extent. This clinically
oriented analysis discusses these important issues in the light of published literature and gives directions on future
areas of research.

INTRODUCTION:

results, unrelated title/abstract, short commentaries, and
inaccessible full articles. Finally, 25 full-text articles were
included in this review. We also examined the references
of the included articles and four additional articles were
included in this review.

Stroke is the most common identified cause of
secondary epilepsy in elderly patients [1-2]. In 1864,
Hugling Jackson first observed an association of seizures
in patients suffering from stroke and in 1885, William
Gowers first described “post-hemiplegic epilepsy” [3].
Post-stroke seizures (PSS) not only increase mortality
and morbidity in patients with stroke but these patients
also have increased disability at discharge and have an
extended hospital stay as compared to stroke patients
without PSS [4]. In the last few decades, multiple studies
have been done to underline the association of stroke
and the relation of multiple risk factors with the
development of PSS but a lot of ground is yet to be
covered.

CLASSIFICATION & PATHOPHYSIOLOGY
Post-stroke seizures are divided into two main types, the
acute symptomatic seizure (ASS) and unprovoked
seizure (US). This distinction is important due to their
different presumed pathophysiology and long-term risk of
seizure recurrence [5], which is approximately 20% after a
single ASS and 71% after the first US [6]. These types are
also referred to in the literature as early-onset and
late-onset PSS, respectively, but the former terms are
preferred and will be used in this review.
ASS is defined as a seizure occurrence within seven days
of stroke [7-8]. However, in different studies, this time
duration defined for ASS varies, ranging from 24 hours to
28 days [7]. ASS is presumed to occur as a result of acute
transient biochemical cellular changes secondary to
neuronal ischemia. These changes include ion channel
dysfunction,
intracellular
calcium
accumulation,
glutamate excitotoxicity, and disruption of the blood-brain
barrier [9]. The surrounding ischemic penumbra, being an
electrically irritable tissue, also functions as an
epileptogenic area [3].
US is defined as a seizure occurrence after seven days of

MATERIALS AND METHODS:
An online literature search was conducted through the
Medline
database
and
Cochrane
library
(PubMed/Cochrane library). We used the following search
keywords terms: “poststroke epilepsy”, OR “poststroke
seizure”, OR “epilepsy after stroke”, OR “seizure after
stroke”. We included the articles that were published in
English, contain human specimens, and carried out in
adults above 18 years from January 2000 to June 2019.
Our search retrieved a total of 897 results, with 885 in
PubMed and 12 reviews in the Cochrane library. 842
results out of 897 were excluded due to duplicate
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infarct, young age and seizure in the early period after
stroke. Despite an increased risk of seizures in these
groups, prophylactic treatment with anti-epileptic drugs
is not recommended. This will be further discussed in the
next section.

stroke [7]. The probability of recurrence of seizures after a
single US is at least 60% over the next 10 years (similar
to the general recurrence risk after two unprovoked
seizures), therefore, the post-stroke patients with US can
be labeled as having post-seizure epilepsy (PSE) even
after one US, as defined by the International League
Against Epilepsy [7]. The same is not true for ASS, which
has a lower risk of seizure recurrence and is not
associated with an adverse clinical outcome after stroke
[10]
. The pathophysiology of US is presumed to be due to
chronic inflammation, neurodegeneration, and gliosis
with the associated remodeling of synaptic networks.
These changes result in neuronal hyperexcitability,
neuronal hypersynchrony, and resultant increased risk of
seizures [9].

Stroke type
Hemorrhagic strokes are reported to have a higher
incidence of PSS as compared to ischemic strokes. A
large 5-year follow-up study in Taiwan reported
post-stroke epilepsy in 4.3% of patients with
hemorrhagic stroke, 4.2% of patients with subarachnoid
hemorrhage and only 1.6% of patients with ischemic
stroke. However, the incidence was the highest (7.7%)
for patients with strokes of multiple subtypes – mostly
hemorrhagic as well as ischemic stroke [12]. Ferlazzo et al.
reported a two-fold increased risk of seizures with
hemorrhagic strokes (OR 2.41, 95% CI 1.57–3.69, p <
0.001) in their meta-analysis [15]. An increased risk for
PSS was also reported among patients with
subarachnoid hemorrhage and infarctions with the
hemorrhagic
conversion.
Hemosiderin
deposits
increasing cerebral epileptogenicity, by causing
overproduction of reactive oxygen species and resultant
oxidative stress, is presumed to be the cause of
increased PSS in these patients, although the exact
cause remains largely unknown [16].
Among ischemic strokes, multiple studies found an
increased association of ASS with embolic infarcts as
compared to thrombotic infarcts, but the same results
are not replicated in other studies and this association is
still inconclusive [3].

EPIDEMIOLOGY
Stroke is considered the most common identified cause
of secondary epilepsy. One large epidemiological study
identified stroke as the main etiology in 11% of the
patients with secondary epilepsy [11]. The incidence of
PSS increases with increased follow-up duration after
stroke. Graham et al. followed 3310 patients in the
United Kingdom with the first stroke and calculated an
estimated cumulative risk of PSS of 1.5% at 3-months,
which increased to 12.4% at 10-years [1]. Another large
prospective study in Taiwan reported that 2.6% cases
(109 out of 4126) developed epilepsy during the 5-year
post-stroke follow up. The incidence was highest for the
patients having multiple subtypes of strokes (7.7%) and
was the lowest for patients with ischemic stroke alone
(1.6%) [12].
The incidence of ASS and US varies among different
studies, partly due to heterogeneous study designs,
different defined durations of ASS and US, and variable
follow-up periods. The incidence of ASS has been
reported from 2% to 33% but consistently, more than
half of the ASS occur within the first 24 hours after stroke
[9,13,14]
. Some studies report a higher incidence of ASS in
young male patients, while other studies show no
difference between age and gender [3,10]. The incidence
of US varies from 3% to 67% [9,13,14]. US is more common
between 6 and 12 months after stroke [9], nonetheless,
US may still develop after 10 years post-stroke [3].

Stroke Location:
Strokes with cortical location are more frequently
associated with PSS [3,15]. It increases the relative risk of
PSS by almost four times (OR 3.71, p < 0.001) as
compared to subcortical strokes [15]. Cortical irritation is
presumed to be the cause of higher epileptogenicity of
cortical strokes [3]. Lacunar strokes are also rarely
associated with seizures [17].
STROKE SIZE:
Stroke size is considered one of the risk factors for
post-stroke epilepsy, as the notion goes, the larger the
size of the stroke, the greater the risk of future seizures.
A 10 mm increase in stroke size on CT scan increases
the relative risk of PSS by 16% within 7 years [18]. Large
strokes involving multiple lobes of the brain are
associated with an increased risk of PSS than the strokes
involving single lobe. In the Oxfordshire Community
Stroke Project, PSS was seen in 11% of patients with

Risk factors
Multiple studies related to PSS have stratified data to
identify independent risk factors that predict seizure
occurrence after stroke. Although numbers vary among
studies due to different methodologies and follow-up
periods, some risk factors have been repetitively
identified in most of the studies that include hemorrhagic
stroke type, cortical involvement, anterior circulation
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treatment for ischemic stroke with PSS is not well
studied. Three studies have reported an increased
incidence of PSS with tPA treatment [20-22], while others
have found no association [23]. Naylor et al. reported PSS
in 21 out of 363 patients (5.8%) treated with IV tPA (OR
3.7, p < 0.0001), while 12 out of 93 patients (12.9%)
with intraarterial tPA developed PSS (OR 5.5, p <
0.0001). These numbers were significantly higher as
compared to the patients who were given standard care
without reperfusion therapy (2%) [22].

total anterior circulation infarcts as compared to only 1%
of patients with lacunar strokes [17]. In another study,
56% of the patients developed PSS after malignant
middle cerebral artery (MCA) infarcts and decompressive
hemicraniectomy [2]. However, a few studies have also
failed to establish a significant association between
stroke size and seizures [13].
STROKE SEVERITY:
Most studies agree that severe neurological deficits at
the stroke presentation are associated with an increased
risk of PSS. Stroke severity is measured by different
scales including the Scandinavian Stroke Scale (SSS) [18]
and National Institute of Health Stroke Scale (NIHSS)
[1,9]
. A 10-point decrease in the SSS score increases the
risk of PSS by more than 25% [18]. This is in part
presumed that severe strokes involve multiple lobes of
the brain and are mostly cortical in location.

OTHERS:
Dementia is considered a significant risk factor for US
(OR=4.66), which is presumed to be due to glutamate
[24]
pathway
dysfunction
in
these
patients
.
Antidepressants, antipsychotic or anxiolytic medications
have also been reported to increase the risk of PSS in
some studies [4] but more well-controlled studies are
needed to establish an association of these medicines
with PSS. For unknown reasons, urinary incontinence at
stroke presentation is also associated with PSS [1]. In the
majority
of
studies,
underlying
cardiovascular
comorbidities, for instance, hypertension, diabetes,
hyperlipidemia, and atrial fibrillation, did not increase the
risk of PSS [25]. However, the use of statins decreased the
risk of epilepsy in some studies [26].

ACUTE ASYMPTOMATIC SEIZURES:
Acute asymptomatic seizures or early seizures are
independent risk factors and increase the risk of PSS by
more than four times. (OR 4.43, p < 0.001) [15]. The
same 4-fold increase in PSS after ASS was also reported
by Kammersgaard in the Copenhagen stroke study [18].
Another study reported that after a single ASS, the
10-year risk of US reaches 30% [6].

CAVE SCORE:

AGE:

Given the aforementioned risk factors, Haapaniemi et al.
proposed a scoring system to predict the risk of US in
patients with intracerebral hemorrhage. It carries one
point each for cortical involvement, age < 65 years, the
volume of hemorrhage > 10 ml, and early seizure, with
scores ranging from 0 to 4. The risk of US was calculated
as 0.6%, 3.6%, 9.8%, 34.8% and 46.2% for CAVE
scores 0–4, respectively, as shown in Table 1 [27].

In the Copenhagen stroke study, younger age was
associated with an increased risk of PSS. A 65%
increase in the risk of PSS is reported with a 10-year
decrease in age at stroke onset [18] but similar results
were not reported in other studies [15,19]. The higher
incidence reported in some studies may be due to
increased survival after a stroke rather than an
independent risk factor. Some studies have also reported
that younger individuals tend to have increased number
of larger strokes due to large artery occlusion as
compared to many small artery strokes in elderly, which
may also be one of the reasons for increased risk of PSS
in the younger population.
GENDER:

EEG IN POSTSTROKE SEIZURES:

Although stroke is more common in the male gender, a
significant difference in PSS was not reported between
male and female gender (OR 0.943 for the female sex,
95% CI 0.79–1.13, p = 0.52) [3,15].

The detection of seizures in post stroke setting may not
be straight forward. [28] Patients may not always have
clinically obvious seizures and subtle manifestations
such as intermittent gaze deviation or nystagmus, mild
facial twitching or focal positive sensory symptoms. In
addition, patients may present with intermittent altered

TISSUE PLASMINOGEN ACTIVATOR:
The association of tissue plasminogen activator (tPA)
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mentation resembling delirium. These cases with
sub-clinical seizures can only be definitively diagnosed by
EEG monitoring. [9] The duration of EEG monitoring may
vary from regular (20-45 minutes) or extended (1-2
hours) to continuous long-term (up to 24 hours or
longer). Although some studies have shown long-term
EEG monitoring to be superior in detection of
non-convulsive seizures, there are no definitive
guidelines as of now, regarding the optimum duration of
EEG monitoring in post-stroke patients and the practices
are variable depending on resources and remain
institution based. [28] The various EEG abnormalities that
may be encountered in this setting can be broadly
divided in to: (1) non-specific abnormalities (focal or
diffuse slowing, asymmetric attenuation of faster
frequency activities, including sleep specific activity); [29]
(2) interictal epileptiform abnormalities such as spike
and sharp transients and intermittent periodic discharges
(lateralized, bilateral independent or generalized), all
generally indicating increased probability of having
seizures; and (3) ictal abnormalities (electrographic
seizures). [9]

Treatment with AEDs after a single ASS is not
recommended [5]. The general risk of seizure recurrence
after a single ASS is only 20%, which is almost the same
as for the single US in a general population. Many
neurologists still prefer to initiate AEDs to avoid
complications in the acute stroke setting, especially if a
patient had multiple ASS (within 24 hours) or had
intracerebral hemorrhage [9]. If AEDs are started after a
single ASS, it is recommended that the drugs should be
withdrawn after four weeks of stroke [5,9].
PRIMARY
SEIZURE

FOR

UNPROVOKED

The use of AEDs for the primary prophylaxis for US is not
recommended by ESO [5]. The general risk of first US in a
patient with stroke is only 10%. The risk of US increases
to 46.2% in a patient with intracerebral hemorrhage
having a CAVE score of 4 (i.e. cortical involvement, age
<65 years, volume >10 ml and ASS) [27]. In these
patients, primary prophylaxis for US with AEDs is optional
and may be individualized. After the initiation of AEDs,
another important concern is the time to stop the AEDs
for which the answer is still unclear.

TREATMENT:
Treatment of PSS is generally individualized based on
clinician’s experience and the patient’s condition due to
the lack of multiple randomized controlled trials (RCTs) to
guide therapeutic decisions. The European Stroke
Organization
(ESO)
has
suggested
certain
recommendations to help in the prevention and
management of PSS, based on several observational
studies and few available RCTs [5]. The management of
PSS can be divided into two main categories; (i)
preventive or prophylactic treatment and (ii) symptomatic
treatment.

TREATMENT FOR UNPROVOKED SEIZURE
In previous studies, the single US after stroke did not
constitute post-stroke epilepsy and AEDs were only
started after two or more US [9]. The current literature
suggests that a single US increases the 10-year risk of
seizure recurrence by > 70% [6], and can be labeled as
post-stroke epilepsy after single US [7], therefore, the
initiation of AEDs after the first US is recommended [5].
Regarding the choice of AEDs in PSS, RCTs are not
available to recommend one AED over another.
Generally, an AED is selected based on the patient's
general condition as well as safety profile and adverse
effects related to AED. Carbamazepine and phenytoin are
traditionally used in the treatment of PSS [16] but these
AEDs induce hepatic enzymes, have known interactions
with multiple other drugs, and greater side effects. The
secondary stroke prophylaxis may also be affected since
carbamazepine and phenytoin have interactions with the
newer anticoagulants including apixaban and dabigatran
[26]
. Lamotrigene and levetiracetam are the other options
to treat PSS with better tolerability and less drug-drug
interactions. There was no significant difference in
efficacy when levetiracetam and lamotrigene were
compared with carbamazepine in two separate studies
[31,32]
. Once started, the decision to discontinue AEDs is
individualized. AEDs may be continued permanently as
the risk of seizure recurrence is high after the withdrawal
of drugs [5].

PRIMARY PROPHYLAXIS FOR ACUTE SYMPTOMATIC
SEIZURE
Primary prophylactic treatment for ASS is not
recommended [5,9] because the general risk of developing
ASS in the patients with a stroke is only about 5%, which
is very low [5]. The presence of large volume, cortical
intracerebral hemorrhage increases the risk of ASS to as
much as 35% and a few clinicians may start
anti-epileptic drugs (AEDs) in these selected cases,
however, the risk of ASS is still not significant enough to
recommend primary prophylaxis. Temporary primary
prophylaxis with AEDs after stroke does not decrease the
future risk of US and does not affect the mortality rates
[30]
. On the other hand, AEDs are loaded with significant
side effects. It is also unclear when to stop the AEDs
once they are started prophylactically.
TREATMENT FOR ACUTE SYMPTOMATIC SEIZURE
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FUTURE DIRECTIONS
Despite the advancements made in our understanding of
post-stroke seizures over the years, many questions still
remain elusive. These include: (1) An association of PSS
with the newer reperfusion therapies. (2) Choice of AED
in the management of PSS. (3) Morbidity and mortality
benefits of long-term treatment of unprovoked seizures
with AEDs. Large scale well-controlled randomized trials
are needed to further expand our knowledge and
recommend practice guidelines for better patient care
with PSS
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